Quest Diagnostics SVP & General Counsel Exercises & Sells $5.51M in Shares Under 10b5-1 Plan

Executive Summary

On August 28, 2026, Michael E. Prevoznik, SVP & General Counsel of Quest Diagnostics Inc ($DGX), executed a pre-scheduled Rule 10b5-1 trading plan transaction. The insider exercised stock options for 22,677 shares at a strike price of $112.17 per share and subsequently sold all 22,677 shares across three weighted-average market tranches totaling approximately $5.51 million at an average price of ~$243.11 per share. Additionally, a charitable gift of 1,000 shares was reported.

Transaction Breakdown

• Option Exercise (Code M): 22,677 shares acquired at $112.17 per share (expiring February 18, 2030).
• Open Market Sales (Code S):
  • 16,010 shares sold at a weighted average price of $242.88 ($242.27 – $243.27)
  • 6,237 shares sold at a weighted average price of $243.63 ($243.27 – $244.23)
  • 430 shares sold at a weighted average price of $244.51 ($244.28 – $245.25)
  • Total Sale Proceeds: ~$5,513,082.84
• Charitable Gift (Code G): 1,000 shares transferred at $0.
• Ending Direct Holdings: 36,557 shares direct, plus 5,780 shares held indirectly via 401(k)/SDCP.

Market & Strategic Context

This transaction represents standard option monetization conducted pursuant to a pre-established Rule 10b5-1 trading plan. Because the transactions were planned in advance and comprised an option exercise with immediate disposition, the trading significance is categorized as Low.